RXRX RECURSION PHARMACEUTICALS, INC.
Nasdaq · SEC CIK 1601830 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $8.93M 36 sales by 5 insiders
- Filings on record
- 457 since 2021-07-06, latest 2026-09-16 17:52
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Borgeson Blake | Dir | — | $4.10M |
| Gibson Christopher | Dir | — | $3.84M |
| Khan Najat | Chief R, D Commercial Off, Dir | — | $806.7K |
| Taylor Ben R | CFO | — | $157.7K |
| Bumpus Namandje | Dir | — | $28.1K |
| Michor Franziska | Dir | — | — |
| Hallett David | CSO | — | — |
| Dar Zavain | Dir | — | — |
| Li Dean Y | Dir | — | — |
| Sun Elaine D | Dir | — | — |
Transactions 743
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-08-19 | 2024-08-15 | RXRX | Marriott Tina | Pres, COO | F - Tax | $6.69 | -14.3K | 521.1K | -3% | -$95.8K | |
| 2024-08-19 | 2024-08-15 | RXRX | Secora Michael | CFO | F - Tax | $6.69 | -12.0K | 1.35M | -0.9% | -$80.0K | |
| 2024-08-19 | 2024-08-15 | RXRX | Mauro David J | Chief Medical Off | F - Tax | $6.69 | -14.1K | 229.6K | -6% | -$94.6K | |
| DM | 2024-08-15 | 2024-08-13+ | RXRX | Secora Michael | CFO | M - OptEx | $2.22 | +78.8K | 1.38M | +6% | +$174.8K |
| DM | 2024-08-15 | 2024-08-13+ | RXRX | Secora Michael | CFO | S - Sale+OE | $6.35 | -30.0K | 1.34M | -2% | -$190.5K |
| DM | 2024-08-09 | 2024-08-07+ | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +50.0K | 778.7K | +7% | $0 |
| DM | 2024-08-09 | 2024-08-07+ | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $6.86 | -50.0K | 758.7K | -6% | -$343.0K |
| 2024-08-08 | 2024-08-06 | RXRX | Borgeson Blake | Dir | S - Sale | $6.82 | -11.4K | 7.14M | -0.2% | -$78.1K | |
| D | 2024-08-05 | 2024-08-01 | RXRX | Khan Najat | Chief R, D Commercial Off, Dir | A - Grant | $0.00 | +497.0K | 497.0K | New | $0 |
| D | 2024-07-29 | 2024-07-25 | RXRX | Marriott Tina | Pres, COO | M - OptEx | $1.06 | +6,000 | 541.5K | +1% | +$6,360 |
| D | 2024-07-29 | 2024-07-25 | RXRX | Marriott Tina | Pres, COO | S - Sale+OE | $8.13 | -6,000 | 535.5K | -1% | -$48.8K |
| 2024-07-25 | 2024-07-23 | RXRX | Borgeson Blake | Dir | S - Sale | $8.48 | -11.4K | 7.16M | -0.2% | -$97.1K | |
| DA | 2024-07-12 | 2024-06-05 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +100.0K | 908.7K | +12% | $0 |
| DM | 2024-07-12 | 2024-07-10+ | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $7.47 | -100.0K | 758.7K | -12% | -$747.5K |
| D | 2024-07-12 | 2024-07-10 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -25.0K | 758.7K | -3% | $0 |
| DM | 2024-07-12 | 2024-07-10+ | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +100.0K | 808.7K | +14% | $0 |
| DM | 2024-07-11 | 2024-07-09+ | RXRX | Secora Michael | CFO | M - OptEx | $2.22 | +78.8K | 1.33M | +6% | +$174.8K |
| DM | 2024-07-11 | 2024-07-09+ | RXRX | Secora Michael | CFO | S - Sale+OE | $7.28 | -30.0K | 1.32M | -2% | -$218.4K |
| 2024-07-11 | 2024-07-09 | RXRX | Borgeson Blake | Dir | S - Sale | $7.32 | -11.4K | 7.17M | -0.2% | -$83.8K | |
| 2024-07-03 | 2024-07-01 | RXRX | Borgeson Blake | Dir | A - Grant | $0.00 | +1,441 | 7.18M | +0.0% | $0 | |
| 2024-07-03 | 2024-07-01 | RXRX | Li Dean Y | Dir | A - Grant | $0.00 | +1,592 | 73.8K | +2% | $0 | |
| 2024-07-03 | 2024-07-01 | RXRX | Burrell Terry-Ann | Dir | A - Grant | $0.00 | +1,843 | 71.3K | +3% | $0 | |
| 2024-07-03 | 2024-07-01 | RXRX | Dar Zavain | Dir | A - Grant | $0.00 | +1,843 | 104.0K | +2% | $0 | |
| D | 2024-06-28 | 2024-06-27 | RXRX | Marriott Tina | Pres, COO | M - OptEx | $1.06 | +6,000 | 541.5K | +1% | +$6,360 |
| D | 2024-06-28 | 2024-06-27 | RXRX | Marriott Tina | Pres, COO | S - Sale+OE | $7.22 | -6,000 | 535.5K | -1% | -$43.3K |
| 2024-06-27 | 2024-06-25 | RXRX | Borgeson Blake | Dir | S - Sale | $9.51 | -11.4K | 7.18M | -0.2% | -$108.9K | |
| DM | 2024-06-17 | 2024-06-13+ | RXRX | Secora Michael | CFO | S - Sale+OE | $9.29 | -30.0K | 1.27M | -2% | -$278.9K |
| DM | 2024-06-17 | 2024-06-13+ | RXRX | Secora Michael | CFO | M - OptEx | $2.22 | +78.8K | 1.26M | +7% | +$174.8K |
| 2024-06-13 | 2024-06-11 | RXRX | Borgeson Blake | Dir | S - Sale | $8.45 | -11.4K | 7.19M | -0.2% | -$96.7K | |
| D | 2024-06-07 | 2024-06-05 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +25.0K | 833.7K | +3% | $0 |
| D | 2024-06-07 | 2024-06-05 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -25.0K | 808.7K | -3% | $0 |
| DM | 2024-06-07 | 2024-06-05+ | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $8.71 | -100.0K | 708.7K | -12% | -$871.0K |
| D | 2024-06-05 | 2024-06-03 | RXRX | HERSHBERG ROBERT | Dir | A - Grant | $0.00 | +13.1K | 51.7K | +34% | $0 |
| D | 2024-06-05 | 2024-06-03 | RXRX | Li Dean Y | Dir | A - Grant | $0.00 | +13.1K | 72.2K | +22% | $0 |
| D | 2024-06-05 | 2024-06-03 | RXRX | Borgeson Blake | Dir | A - Grant | $0.00 | +13.1K | 7.20M | +0.2% | $0 |
| D | 2024-06-05 | 2024-06-03 | RXRX | Dar Zavain | Dir | A - Grant | $0.00 | +13.1K | 102.2K | +15% | $0 |
| D | 2024-06-05 | 2024-06-03 | RXRX | Burrell Terry-Ann | Dir | A - Grant | $0.00 | +13.1K | 69.4K | +23% | $0 |
| D | 2024-06-03 | 2024-05-30 | RXRX | Marriott Tina | Pres, COO | M - OptEx | $1.06 | +3,000 | 538.5K | +0.6% | +$3,180 |
| D | 2024-06-03 | 2024-05-30 | RXRX | Marriott Tina | Pres, COO | S - Sale+OE | $8.78 | -3,000 | 535.5K | -0.6% | -$26.3K |
| 2024-05-30 | 2024-05-28 | RXRX | Borgeson Blake | Dir | S - Sale | $9.17 | -11.4K | 7.19M | -0.2% | -$105.0K | |
| 2024-05-17 | 2024-05-15 | RXRX | Secora Michael | CFO | F - Tax | $10.01 | -12.0K | 1.22M | -1.0% | -$119.7K | |
| 2024-05-17 | 2024-05-15 | RXRX | Mauro David J | Chief Medical Off | F - Tax | $10.01 | -867 | 243.8K | -0.4% | -$8,679 | |
| 2024-05-17 | 2024-05-15 | RXRX | Marriott Tina | Pres, COO | F - Tax | $10.01 | -9,998 | 533.2K | -2% | -$100.1K | |
| 2024-05-17 | 2024-05-15 | RXRX | Gibson Christopher | CEO, Dir | F - Tax | $10.01 | -26.1K | 808.7K | -3% | -$261.1K | |
| 2024-05-16 | 2024-05-14 | RXRX | Borgeson Blake | Dir | S - Sale | $10.12 | -20.1K | 7.20M | -0.3% | -$202.9K | |
| DM | 2024-05-03 | 2024-05-01+ | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $8.10 | -100.0K | 834.8K | -11% | -$810.0K |
| D | 2024-05-03 | 2024-05-02 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +21.3K | 856.1K | +3% | $0 |
| D | 2024-05-03 | 2024-05-01 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -25.0K | 913.5K | -3% | $0 |
| 2024-05-02 | 2024-04-30 | RXRX | Borgeson Blake | Dir | S - Sale | $7.95 | -11.4K | 7.22M | -0.2% | -$91.0K | |
| D | 2024-04-29 | 2024-04-25 | RXRX | Marriott Tina | Pres, COO | S - Sale+OE | $7.67 | -3,000 | 543.2K | -0.5% | -$23.0K |
| D | 2024-04-29 | 2024-04-25 | RXRX | Marriott Tina | Pres, COO | M - OptEx | $1.06 | +3,000 | 546.2K | +0.6% | +$3,180 |
| DM | 2024-04-18 | 2024-04-16+ | RXRX | Secora Michael | CFO | S - Sale+OE | $7.63 | -48.1K | 1.22M | -4% | -$367.0K |
| DM | 2024-04-18 | 2024-04-16+ | RXRX | Secora Michael | CFO | M - OptEx | $2.22 | +75.0K | 1.24M | +6% | +$166.5K |
| 2024-04-18 | 2024-04-16 | RXRX | Borgeson Blake | Dir | S - Sale | $7.66 | -11.4K | 7.23M | -0.2% | -$87.7K | |
| D | 2024-04-05 | 2024-04-03 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -25.0K | 1.02M | -2% | $0 |
| DM | 2024-04-05 | 2024-04-03+ | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $8.93 | -80.0K | 938.5K | -8% | -$714.4K |
| DMI | 2024-04-05 | 2024-04-03+ | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +50.0K | 25.0K | New | $0 |
| DMI | 2024-04-05 | 2024-04-03+ | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $8.93 | -50.0K | 0 | -100% | -$446.5K |
| 2024-04-03 | 2024-04-01 | RXRX | CHAVEZ R. MARTIN | Dir | A - Grant | $0.00 | +2,001 | 60.1K | +3% | $0 | |
| 2024-04-03 | 2024-04-01 | RXRX | Li Dean Y | Dir | A - Grant | $0.00 | +1,267 | 59.1K | +2% | $0 | |
| 2024-04-03 | 2024-04-02 | RXRX | Borgeson Blake | Dir | S - Sale | $8.82 | -11.4K | 7.24M | -0.2% | -$101.0K | |
| 2024-04-03 | 2024-04-01 | RXRX | Burrell Terry-Ann | Dir | A - Grant | $0.00 | +1,467 | 56.3K | +3% | $0 | |
| 2024-04-03 | 2024-04-01 | RXRX | Dar Zavain | Dir | A - Grant | $0.00 | +1,467 | 89.1K | +2% | $0 | |
| DI | 2024-04-01 | 2024-03-28 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +25.0K | 25.0K | New | $0 |
| D | 2024-04-01 | 2024-03-28 | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $10.10 | -40.0K | 1.04M | -4% | -$404.0K |
| D | 2024-04-01 | 2024-03-28 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -25.0K | 1.08M | -2% | $0 |
| DI | 2024-04-01 | 2024-03-28 | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $10.10 | -25.0K | 0 | -100% | -$252.5K |
| D | 2024-03-25 | 2024-03-21 | RXRX | Marriott Tina | Pres, COO | M - OptEx | $1.06 | +8,000 | 648.0K | +1% | +$8,480 |
| DM | 2024-03-25 | 2024-03-21 | RXRX | Marriott Tina | Pres, COO | S - Sale+OE | $10.75 | -8,000 | 640.6K | -1% | -$86.0K |
| 2024-03-21 | 2024-03-19 | RXRX | Borgeson Blake | Dir | S - Sale | $10.79 | -20.1K | 7.25M | -0.3% | -$216.4K | |
| DM | 2024-03-14 | 2024-03-12+ | RXRX | Secora Michael | CFO | S - Sale+OE | $10.74 | -50.0K | 1.19M | -4% | -$537.2K |
| DM | 2024-03-14 | 2024-03-12+ | RXRX | Secora Michael | CFO | M - OptEx | $2.22 | +75.0K | 1.22M | +7% | +$166.5K |
| DMI | 2024-03-08 | 2024-03-06 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $11.55 | -25.0K | 0 | -100% | -$288.8K |
| DMI | 2024-03-08 | 2024-03-06 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +25.0K | 4,000 | New | $0 |
| D | 2024-03-08 | 2024-03-06 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -10.0K | 1.10M | -0.9% | $0 |
| DM | 2024-03-08 | 2024-03-06 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $4.42 | +39.9K | 1.14M | +4% | +$176.4K |
| D | 2024-03-08 | 2024-03-06 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $11.86 | -36.3K | 1.11M | -3% | -$430.7K |
| D | 2024-03-08 | 2024-03-06 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +10.0K | 1.11M | +0.9% | $0 |
| 2024-03-07 | 2024-03-05 | RXRX | Borgeson Blake | Dir | S - Sale | $12.06 | -20.1K | 7.27M | -0.3% | -$241.9K | |
| D | 2024-02-23 | 2024-02-22 | RXRX | Marriott Tina | Pres, COO | M - OptEx | $1.06 | +8,000 | 648.0K | +1% | +$8,480 |
| D | 2024-02-23 | 2024-02-22 | RXRX | Marriott Tina | Pres, COO | S - Sale+OE | $14.90 | -8,000 | 640.0K | -1% | -$119.2K |
| M | 2024-02-21 | 2024-02-20 | RXRX | Borgeson Blake | Dir | S - Sale | $12.32 | -20.1K | 7.29M | -0.3% | -$247.1K |
| 2024-02-16 | 2024-02-15 | RXRX | Gibson Christopher | CEO, Dir | F - Tax | $12.43 | -11.1K | 1.10M | -1.0% | -$138.6K | |
| 2024-02-16 | 2024-02-15 | RXRX | Marriott Tina | Pres, COO | F - Tax | $12.43 | -5,379 | 640.0K | -0.8% | -$66.9K | |
| 2024-02-16 | 2024-02-15 | RXRX | Secora Michael | CFO | F - Tax | $12.43 | -7,172 | 1.18M | -0.6% | -$89.1K | |
| DM | 2024-02-15 | 2024-02-13+ | RXRX | Secora Michael | CFO | S - Sale+OE | $10.16 | -50.0K | 1.19M | -4% | -$507.8K |
| DM | 2024-02-15 | 2024-02-13+ | RXRX | Secora Michael | CFO | M - OptEx | $2.22 | +75.0K | 1.20M | +7% | +$166.5K |
| DM | 2024-02-13 | 2024-02-09 | RXRX | Mauro David J | Chief Medical Off | A - Grant | $0.00 | +55.8K | 196.8K | +40% | $0 |
| D | 2024-02-13 | 2024-02-09 | RXRX | Mauro David J | Chief Medical Off | F - Tax | $10.09 | -1,892 | 244.6K | -0.8% | -$19.1K |
| D | 2024-02-13 | 2024-02-09 | RXRX | Secora Michael | CFO | F - Tax | $10.09 | -2,512 | 1.16M | -0.2% | -$25.3K |
| DM | 2024-02-13 | 2024-02-09 | RXRX | Secora Michael | CFO | A - Grant | $0.00 | +182.8K | 989.7K | +23% | $0 |
| D | 2024-02-13 | 2024-02-09 | RXRX | Marriott Tina | Pres, COO | F - Tax | $10.09 | -2,800 | 645.4K | -0.4% | -$28.3K |
| DM | 2024-02-13 | 2024-02-09 | RXRX | Marriott Tina | Pres, COO | A - Grant | $0.00 | +233.6K | 424.2K | +123% | $0 |
| DM | 2024-02-13 | 2024-02-09 | RXRX | Gibson Christopher | CEO, Dir | A - Grant | $0.00 | +344.6K | 1.12M | +44% | $0 |
| D | 2024-02-13 | 2024-02-09 | RXRX | Gibson Christopher | CEO, Dir | F - Tax | $10.09 | -3,233 | 1.12M | -0.3% | -$32.6K |
| D | 2024-02-09 | 2024-02-07 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $9.22 | -48.3K | 774.7K | -6% | -$445.1K |
| D | 2024-02-09 | 2024-02-07 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 823.0K | +4% | +$77.5K |
| D | 2024-02-09 | 2024-02-07 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -10.0K | 791.7K | -1% | $0 |
| D | 2024-02-09 | 2024-02-07 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +10.0K | 801.7K | +1% | $0 |
| 2024-02-08 | 2024-02-06 | RXRX | Borgeson Blake | Dir | S - Sale | $9.30 | -11.4K | 7.31M | -0.2% | -$106.5K |
Purchase Sale Sale after option exercise All abbreviations